Pfizer’s Ibrance approved by NICE, to be added to the Cancer Drugs Fund
November 28, 2019Manufacturing and Production, Research and Development Cancer Drugs Fund, NHS, NICE, Pfizer, breast cancer, ibrance, pharma
Today it was announced that the National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Ibrance (palbociclib) to …
US prosecutors open criminal probe of six drugs companies in opioid investigation
November 28, 2019Business Services, Manufacturing and Production Federal Substance Act, Opiod, Trump, Trump Opiod, opiod crisis
Federal Prosecutors from the US Attorney’s Office in the Eastern District of New York have subpoenaed five opioid manufactures. The …
Corbyn reveals documents showing US-UK meetings on deregulating NHS drug pricing
November 27, 2019Research and Development, Sales and Marketing Jeremy Corbyn, Labour Party, NHS, US, pharma
Labour Leader Jeremy Corbyn has showed off documents that detail secret trade meetings between the US and UK Governments, where …
Organisation of Islamic Cooperation sets up new halal pharmaceuticals technical committee
November 27, 2019Research and Development Arabic, Halal, Organisation of Islamic Cooperation, Saudi Arabia, malaysia
The Organisation of Islamic Cooperation’s (OIC) standards body, the Standards and Metrology Institute for Islamic Countries (SMIIC), has set up …
New ICER report reveals most cost-effective rheumatoid arthritis therapies
November 27, 2019Research and Development, Sales and Marketing AbbVie, Eli Lilly, Humira, Olumiant, Pfizer, Rinvoq, Xeljanz, pharma
The Institute for Clinical and Economic Review (ICER) has unveiled a new report comparing the clinical efficacy and cost-effectiveness of …
NICE rejects Keytruda for routine use in NHS bladder cancer treatment
November 27, 2019Research and Development Cancer Drugs Fund, bladder cancer, cancer research
The National Institute for Health and Care Excellence (NICE) has given an initial ‘no’ for Keytruda’s (pembrolizumab) use in treating …
AstraZeneca and Novoheart team up to develop human ‘heart-in-a-jar’
November 27, 2019Research and Development Heart in a Jar, Novoheart, heart disease
AstraZeneca and Novoheart are collaborating on developing a functioning miniature human heart model of heart failure, a first of its …
FDA approves GBT’s Oxbryta to treat sickle cell disease
November 26, 2019Manufacturing and Production FDA, FDA Trump, Oxbryta, Sickle cell, sickle cell disease
The FDA announced yesterday that it has approved Global Blood Therapeutics’ marketing application for its haemoglobin polymerisation inhibitor Oxbryta, which …
Singapore and South Korea agree to cooperate on Good Manufacturing Practice
November 26, 2019Manufacturing and Production ASEAN, GMP, North Korea, ROK, Singapore, south korea
At a joint summit on Saturday, South Korea’s Ministry of Food and Drug Safety signed a memorandum of understanding (MOU) …
US lawmakers call for FDA office in Israel
November 26, 2019Manufacturing and Production FDA, Golan Heights, Israel FDA, Netanyahu, Trump, USA, congress, israel
A bipartisan group of 21 US members of Congress has called for the establishment of an FDA office in Israel, …
Europe approves first subcutaneous version of biosimilar infliximab
November 26, 2019Manufacturing and Production, Sales and Marketing arthritis, biosimilars, celltrion, infliximab, pharma
The European Commission has chosen to authorise Celltrion Healthcare’s Remsima SC, a biosimilar of infliximab and the first subcutaneous formulation …
Conservatives pledge to invest in preventing and curing disease in election manifesto
November 26, 2019Manufacturing and Production Boris Johnson, Conservative Party, Election 2019, Tories NHS, Tory Manifesto
Prime Minister Boris Johnson launched the Conservative Party’s manifesto on Sunday, promising to invest more into research to prevent and …
The coming age of biosimilars
November 25, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biosimilars, feature, pharma
With more and more biosimilars securing approval and the sheer potential value they have to offer for healthcare systems around …
Sanofi’s head of strategy and business development to retire amid company review
November 25, 2019Sales and Marketing Bristol Meyers, Gilead, Sanofi, Shell
One of Sanofi’s most senior strategy bosses is set to retire at the end of the month. Muzammil Mansuri, Executive …
FDA approves AstraZeneca’s Calquence in chronic lymphoma
November 25, 2019Sales and Marketing Astrazenaca, Calquence, FDA, Health Canada, leukaemia, oncology
The FDA has approved AstraZeneca’s BTK inhibitor Calquence (acalabrutinib) in the treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic …
FDA fast-tracks psilocybin treatment for major depressive disorder
November 25, 2019Sales and Marketing Controlled Substance Act, FDA, breakthrough therapy, major depressive disorder, psilocybin
The FDA has granted a Breakthrough Therapy designation to the Usona Institute for its trial use of psilocybin in the …
Novartis acquires The Medicines Company in a deal worth $9.7 billion
November 25, 2019Sales and Marketing Novartis, The Medicines Company, pharma
Novartis agreed a $9.7 billion deal to acquire the US-based The Medicines Company, it announced Sunday. The transaction was unanimously …
Roche’s Tecentriq combo outclasses Nexavar in unresectable hepatocellular carcinoma
November 25, 2019Research and Development, Sales and Marketing Cancer, Roche, immunotherapy, pharma, tecentriq
Roche has revealed new Phase 3 data for its immunotherapy drug Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) in the …
Scotland leading the UK in life science start-up growth, report reveals
November 20, 2019Research and Development, Sales and Marketing BioCity, UK, biotech, pharma
A new report published by the life science incubator and business collective BioCity has painted a promising picture of UK …
Lilly to boost Indianapolis manufacturing site with $400m injection, 100 jobs to be created
November 20, 2019Manufacturing and Production, Research and Development Eli Lilly, US, pharma
Eli Lilly is poised to boost its manufacturing capacity with the investment of $400 million at its Lilly Technology Center …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
